Finally, there is a clear need to extend the development of targeted therapies beyond animal models to include human clinical trials, ensuring that treatments addressing ET-1’s role in glaucoma can be effectively translated into therapeutic options that mitigate disease progression. The gene discussed is EDN1; the disease is glaucoma.